Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      NPPA says Abbott can discontinue Xience Alpine stent in a year, check out details

      NPPA says Abbott can discontinue Xience Alpine stent in a year, check out details

      Ruby Khatun Khatun27 Sept 2017 12:42 PM IST
      New Delhi: Through a recent notice, Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, and National...
      Tata ready with tech to reverse antibiotic resistance

      Tata ready with tech to reverse antibiotic resistance

      Ruby Khatun Khatun26 Sept 2017 1:54 PM IST
      New Delhi: To fund cutting-edge technology in healthcare, Tata Industries Ltd collaborated with Tel Aviv University Ltd (Ramot) and after four years...
      Zydus Cadila gets USFDA nod to sell BP lowering drug

      Zydus Cadila gets USFDA nod to sell BP lowering drug

      Ruby Khatun Khatun26 Sept 2017 10:49 AM IST
      New Delhi: Cadila Healthcare on Saturday said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood...
      Novartis India board clears share buyback worth Rs 231 crore

      Novartis India board clears share buyback worth Rs 231 crore

      Ruby Khatun Khatun26 Sept 2017 10:34 AM IST
      New Delhi: Drug firm Novartis India on Monday said its board has approved buyback of up to 34.5 lakh shares, accounting for about 12.26 percent of the...
      Suven Life Sciences gets neuro patent from India, Japan

      Suven Life Sciences gets neuro patent from India, Japan

      Ruby Khatun Khatun26 Sept 2017 10:29 AM IST
      New Delhi: Drug firm Suven Life Sciences has been granted a patent each by India and Japan for a drug used in the treatment of neurodegenerative...
      Perrigo gets FDA final approval for generic version of Exalgo® 32mg extended release tablets

      Perrigo gets FDA final approval for generic version of Exalgo® 32mg extended release tablets

      Ruby Khatun Khatun26 Sept 2017 9:51 AM IST
      DUBLIN: Perrigo Company plc announced it has received final approval from the U.S. Food and Drug Administration (FDA) for its AB-rated Abbreviated New...
      AbbVie, Bristol-Myers announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

      AbbVie, Bristol-Myers announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

      Ruby Khatun Khatun26 Sept 2017 9:26 AM IST
      NORTH CHICAGO, Ill. and NEW YORK: AbbVie and Bristol-Myers Squibb Company announced a clinical trial collaboration to evaluate the combination of...
      Chemist prescribing OTC medicines: Drug advisory body gives in-principle approval

      Chemist prescribing OTC medicines: Drug advisory body gives in-principle approval

      Ruby Khatun Khatun25 Sept 2017 1:41 PM IST
      New Delhi: The proposal to introduce a new category of over the counter (OTC) medicines which will empower the pharmacists to dispense drugs for minor...
      Company to pay 35 million dollar for falsely marketing cholesterol drug

      Company to pay 35 million dollar for falsely marketing cholesterol drug

      Ruby Khatun Khatun25 Sept 2017 10:42 AM IST
      BOSTON: A Massachusetts drug company has agreed to pay more than $35 million to resolve criminal and civil charges that it falsely marketed a...
      Glenmark expects generics to drive growth over next 3 yrs

      Glenmark expects generics to drive growth over next 3 yrs

      Ruby Khatun Khatun25 Sept 2017 10:37 AM IST
      Mumbai: Pharma firm Glenmark Pharmaceuticals has said its pipeline of specialty and innovative products over the next three to four years is expected...
      Roche cancer immunotherapy Tecentriq wins EU approval

      Roche cancer immunotherapy Tecentriq wins EU approval

      Ruby Khatun Khatun25 Sept 2017 10:17 AM IST
      ZURICH: Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.The...
      Early, rapid and reliable blood tests are the best way to fight dengue outbreak

      Early, rapid and reliable blood tests are the best way to fight dengue outbreak

      Ruby Khatun Khatun25 Sept 2017 9:47 AM IST
      Mumbai: Following the water deluge on August 29, Mumbaikars are now facing a deluge of Dengue cases. In the first fortnight of September itself, 1,659...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok